



SensUs

A hand holds a microfluidic chip while a pipette dispenses liquid into one of its wells. The chip has several circular wells and a central rectangular area with some markings.

SensUs 2019
PROGRAM

CONTENT


Floor Plan	2
Program	3
Welcome	5
SensUs Organization	6
What is SensUs?	7
Theme & Biomarker	8
Speakers	9
Workshop	10
SensUs Teams	13
Universities	22
Awards	23
Jury	24
Partners	25
SensUs Article	27
Closing	30



FLOOR PLAN



All locations are in the Atlas building.



PROGRAM

Workshops

-1.715

Symposium

0.820 / 0.825

High Schools Project

Workshop 1
ReumaZorg
Nederland

Workshop 2
Slimmer Leven

Workshop 3
Peter Joosten

12.30
12.45

Opening
Meet the SensUs teams

13.30

Nanoparticles: new
immunological
medicines

14.45

Sensor technology for
continuous immuno-
monitoring

15.30

Biomarkers & big data
for clinical immunology

16.15

Immunodiagnostics,
past, present, future

17.30

Discussion: Translations
to clinic, how and when
0.710

18:00

Closure

13.00

1-minute Pitches

Stage 1: -1.820

13.30

Poster Presentations
Hall

15.30

16.15

Closing SensUs
with award ceremony
High Schools Project
0.820 / 0.825

17.30

*“0” means ground floor
“-1” means basement*

WELCOME

Prof. dr. Menno Prins

Founder of SensUs



Welcome visitors and participants of SensUs 2019! We are going to admire 14 student teams from universities in North America, Asia, Africa, and Europe, that have developed sensors for the measurement of a very important drug to treat rheumatic disease. In SensUs the students learn how to be courageous, work together, make real prototypes, and analyze applications in healthcare. University professors, companies, healthcare professionals, and patients play their parts. SensUs brings us all together in order to learn about innovation. Thank you for being here and I wish you a lively and inspiring SensUs Innovation Day!

Kirsten Peeters

Chair of SensUs



Welcome to SensUs 2019! After a year of hard work from both the teams and the organization, the finals of the fourth edition of the SensUs student competition are finally here! The SensUs organization is a group of students aiming to bring people and knowledge together, in order to innovate the field of biosensors. It makes me very proud to see what these students did to make SensUs 2019 possible and I am confident it will be a great success. I am looking forward to the upcoming days, to this unforgettable experience in which we all strive to improve healthcare and the quality of life of patients. On behalf of the whole organization, I wish you an amazing and inspiring time at the SensUs Innovation Days. Together, let's bring a boost to the innovation in sensors for health!

THE ORGANIZATION



Chairs & Co

Yannick Leurs
Kirsten Peeters
Maria Pop
Aaron Saam



Public Relations

Isabel van der Steenhoven
Job van Helvoirt
Julia Geschiere
Suzanne Ansems
Jorrit Baartman



External Relations

Cecile van Riele
Vincent Eurlings
Roderick Haarselhorst
Teun van Acker



Technology

Hanna Merényi
Marloes Coolen
Myrthe Kater
Jojanne van Leeuwen



Events

Rutger van Doorslaer
Judith Hoekstra
Julia van der Vleuten
Maaïke Konig



Strategy & Innovation

Tamar van Asch
Eliene Rutten
Bart Engelen
Abel Goedegebuure
Luuk Kemna

WHAT IS SENSUS?

The future of healthcare

An important aim in healthcare is to keep people healthy as long as possible and to enable people in need of care to live a high-quality life in their own environments. Healthcare is developing toward a world wherein care is delivered in a highly personalized manner, attuned to the status of the patient, based on actual, precise and reliable data. This is where biosensors play a big role.

Our mission

The mission of SensUs is to stimulate the development of biosensors in a friendly competitive manner whereby students design and make innovative biosensors. Each year a different healthcare theme is selected. The focus of SensUs 2019 is on rheumatic disease.

The teams

The participating teams consist of students from multiple scientific disciplines. Biosensing technologies are inherently multidisciplinary. To be successful, the teams need to creatively combine molecular technologies and device technologies. The style of the competition is 'friendly competitive'. Teams of students compete for different prizes. However, it is equally important that teams learn from each other, share information, and sow seeds for international collaboration.

A platform for collaboration

SensUs stimulates information sharing and community development for continuous innovation in biosensors. It forms a platform for open innovation and welcomes stakeholders such as healthcare organizations, patient organizations, R&D funding organizations, and companies to partner with the competition.



THEME & BIOMARKER

Managing rheumatic disease by measuring with ease

SensUs 2019 challenges student teams to develop innovative biosensing systems for the treatment of rheumatoid arthritis. Rheumatoid arthritis is an inflammatory disorder with a worldwide prevalence of about 1%. The biosensors are specifically developed for the measurement of adalimumab. Adalimumab is the largest selling pharmaceutical drug worldwide and relieves symptoms in many patients suffering from rheumatoid arthritis.

Our mission

Rheumatoid arthritis is characterized by inflammation of small joints, like hands and feet, which leads to the destruction of cartilage and bone. The cause of the disorder is not well understood, but the overexpression of pro-inflammatory molecules plays an important role. One pro-inflammatory molecule that plays a key role is TNF-alpha.

The teams

The fourteen participating teams will demonstrate biosensors for the detection of adalimumab. Adalimumab is a protein-based drug that binds to TNF-alpha. The drug suppresses inflammation and thereby relieves the symptoms of rheumatic disease. Adalimumab is a very expensive biological drug. However, it is not an adequate treatment for every patient. Patients may not have benefits or may even lose treatment benefits over time. A biosensor that can precisely measure the level of adalimumab in a patient's blood is expected to be of great value for optimally managing the rheumatic disease.

SPEAKERS



Master of Ceremonies

Annabel Romijn

Annabel Romijn (1994) obtained her M.Sc. degree in Applied Physics in 2018 from Eindhoven University of Technology (TU/e). In 2019, she obtained her second M.Sc. degree in Science Education & Communication. During her time at TU/e, she worked as a student advisor to advertise the TU/e. Examples include presentations during the lustrum dies in 2016, at the Graduate School event and at the information days together with members of the executive board and the rector magnificus.

Additionally, she has led multiple scientific events as moderator such as TEDxEindhoven, Famelab and Pint of Science. Recently, she also got chosen as one of the participants in Expedition Spinvis and as Young European Talent. Since August, she works as a physics teacher 4 days a week and 1 day a week as freelance moderator & photographer.



Keynote Speaker

Marien de Jonge

The immunological system is involved in many different diseases ranging from infection and inflammation to cancer and cardiovascular disorders, ranging from acute to chronic illness. In the past diagnosis relied on single biomarkers and complex time-consuming diagnostic assays. Currently, multidisciplinary teams are conducting studies to investigate immune regulation and develop new methods and technologies to measure dynamic profiles of immune parameters. This will enable us, in

the near future, to better predict the course of disease to facilitate treatment stratification and to provide improved personalized health care.

Dr. Marien de Jonge is Associate Professor at Radboud University Medical Center, head of section Pediatric Infectious Diseases, and has a background in both academic research and industrial R&D.

WORKSHOPS

Workshop 1 | Rheumatoid arthritis patients

ReumaZorg Nederland

What does it feel like to have rheumatoid arthritis (RA)? What symptoms are you confronted with? What does a treatment look like, but most of all ... what does it do with your life?

About 30 years ago rheumatism was symbolized by joint swelling and a wheelchair. This is not the case anymore thanks to medication. However, rheumatism still cannot be cured. Almost 23 million people are fighting against inflammation, pain and fatigue.

In this workshop, given by ReumaZorg Nederland, two patients with RA share their personal story. They show their lives before and after the diagnosis of RA. How do they manage to enjoy life despite their condition?

Workshop 2 | Design thinking & co-creation

Slimmer Leven

Design Thinking is the corner stone of many innovation projects. This workshop will provide you with three methods that can be found in the designer's tool kit! One method is about creating ideas, the other two with the aim to test those ideas. See you there!

Workshop 3 | Biohacking

Peter Joosten

What are major developments in biohacking and human enhancement? Biohacking covers a lot of technologies: from gadgets and wearables, to implants, brain-computer interfacing, artificial intelligence and genetic modification.

How can we judge the impact and effects of human augmentation? During this workshop we discuss the pro's and con's of biohacking, and we seek for a common ethical framework.



Together for
healthy lives
in Europe





Eindhoven Startup Alliance

“CREATING THE HIGH TECH CAPITAL OF THE WORLD”

EINDHOVEN STARTUP ALLIANCE (ESA)


ESA is a collaboration between several large Dutch companies to stimulate startups in the region of Eindhoven. The alliance's goals is to support the startup-accelerator HighTechXL.

“We know how to turn deep-tech into global business. With our skills in the region, we can make the difference to startups active in our target industry applications.” - Rob van der Werf, Co-founder



www.eindhovenstartupalliance.com

SENSUS TEAMS



England
Spain
Sweden
China
Belgium
Denmark
United States of America
Scotland
Netherlands
Germany
Switzerland
Canada
Egypt
Portugal

Imperial College London
Univ. Politecnica de Catalunya + Univ. of Vic
Uppsala University
Zhejiang University
KU Leuven
Technical University Denmark
North Carolina State University
University of Glasgow
Eindhoven University of Technology
RWTH Aachen
École Polytechnique Fédérale de Lausanne
Université de Montréal
The American University in Cairo
University of Lisbon

Joint Venture Imperial College London



SensingBarcelona UPC + UVic



SENSUS TEAMS

AdUpSense
Uppsala University



TruSense
Zhejiang University



SynoSense KU Leuven



DeTectUs Technological University Denmark



SENSUS TEAMS

SenseNC

North Carolina State University



Glensor

University of Glasgow



T.E.S.T

Eindhoven University of Technology



AixSense

RWTH Aachen



SENSUS TEAMS

EPFSens

Ecole Polytechnique Fédérale de Lausanne



BiosensUM

Université de Montréal




AUSense American University in Cairo



LxUs University of Lisbon





UNIVERSITIES





AWARDS

The **Analytical Performance award** goes to the team with the biosensor that functions best, in terms of measurement accuracy, speed, and required sample volume.

The **Creativity award** relates to the technological novelty of the biosensors and to the way how the teams have worked during their development process.

The **Translation Potential award** is about the plans of the teams to bring their biosensor from a prototype to a product that can be used in society. Will the product meet the needs of doctors and patients, and will it be suited for industrial production?

The **Public Inspiration award** gives recognition to the teams that best inspire the public. The award is based on the votes from the worldwide public, who see on SensUs Digital the presentations, pitches and demonstrations of the teams.

JURY

Jury Process

The Analytical Performance award and Public Inspiration award are based on numerical data. The Creativity award and Translation Potential award are based on judgments by members of the jury. The jury consists of people from universities, companies, healthcare, and innovation organizations.

Jury Composition

Creativity Awards

Steven Staal, Medimate

Maarten Broeren, clinical chemist

Jean-François Masson, university representative Canada

Stefano Menegatti, university representative USA

Hugo Ferreira, university representative Portugal

Sven Ingebrandt, university representative Germany

Leo van IJzendoorn, university representative the Netherlands

Jasmina Casals, university representative Spain

Hassan Azzazy, university representative Egypt

Translation Potential - Stakeholder Desirability

Luc Derijks, clinical pharmacologist

Carolien Oppeneer, CbusineZ

Frank van den Heuvel, CLB

Renee Meijer & Annemieke Fransz, PatientPartners

Translation Potential - Business Feasibility

Marko Blom, Micronit

Mercedes Tuin, BOM

Menno Kok, EIT Health

Julien Reboud, university representative Scotland

Translation Potential - Financial Viability

Annelies Bobelyn, assistant professor TU/e

Guus Frericks, HighTechXL

Jorte Nijboer, MedValue

Leo Smit, ReumaNederland



EIT Health is supported by the EIT,
a body of the European Union



Powered by **ASML**



PARTNERS



SENSUS ARTICLE

Potential use of Biosensing in the Treatment of Rheumatic Disease

By involving students, industry, patients and healthcare professionals, SensUs strives to accelerate the development of sensors for health and to stimulate education and innovation in the field of biosensing. The theme of SensUs 2019 is *Managing rheumatic disease by measuring with ease*. SensUs 2019 challenges teams of students worldwide to develop innovative biosensors for the detection of the anti-inflammatory drug adalimumab. Over the year, we spoke with several stakeholders to deepen our knowledge on rheumatoid arthritis and the usage of adalimumab. Here are brief summaries of the articles:

Both Gerda and Wendy were diagnosed with rheumatoid arthritis when they were very young. Initially, they were not diagnosed with RA, as this is not common among children. Gerda, now 59 years of age, owes a lot to the biologicals she has taken, otherwise she would not have been so mobile right now. This is also one of the reasons why she has never seen her disease as a burden. Wendy is currently a PhD student at Eindhoven University of Technology. She thinks that a biosensor in the field of RA would be of great value, as it is an indication of whether the inflammation is controlled or not.

Keita Ito strongly agrees with this. He is a full professor in Orthopaedic Biomechanics and he says that a downside of rheumatoid arthritis is that it is not possible for patients to monitor their joints. In the past, only the pain was treated, however, the cartilage is worn away slowly, without yourself even noticing. Point of care testing could be of great value to inform patients whether the drug is actually modifying the disease. He mentions that the biosensors have to be patient-proof, only when a patient is happy to use the system, it will work.

Keita Ito: *“ Movement is life, life is movement.”*

A similar opinion on biosensors for rheumatoid arthritis patients is expressed by Judith Kreuk, a rheumatoid arthritis nurse. She guides patients to regain



balance in their daily lives and is socially and emotionally involved with patients. A biosensor, in her opinion, will provide a lot of insights in the patient's treatment.

Judith Kreuk: *“An important challenge in the treatment of RA is to create a situation where the progress of the disease can be predicted.”*

Eric-Jan Kroot is a rheumatologist who says that the trickiest about rheumatoid arthritis is that it is an invisible disease. He has seen a lot of progression within the field of rheumatoid arthritis. Nowadays, rheumatoid arthritis patients do not end up in a wheelchair anymore, in contrast to a few decades ago. In his opinion, a strong part of the SensUs competition is that the teams aim to build the best sensor, without being influenced by other parties.

Luc Derijks is a hospital pharmacist and specializes in autoimmune diseases. He works on personalized medicine in inflammatory bowel disease and rheumatoid arthritis. Both are autoimmune diseases in which the immune system works too hard and attacks cells of the human body. The treatments of these two diseases are very alike. Picking the right drug and the right dose can be very challenging. Tools like therapeutic drug monitoring (TDM) are of help, e.g. for rheumatoid arthritis patients who use the drug adalimumab. Biologicals, such as adalimumab, are very expensive compared to other drugs. The goal is to give each patient the most cost-effective treatment. The drug has to be effective, but it is simply not possible to give everyone a biological, and it is not necessary either.

Luc Derijks: *“The challenge is to give the right dose to the right patients and to avoid unnecessary costs.”*

For their full interviews and personal stories, visit www.sensus.org.



















Carlota Mestre
Saragatxeh
Universitat Politècnica de Catalunya

CLOSING

The SensUs organization would like to thank you for visiting this event. We hope you had an inspiring and innovative time and enjoyed the creations of our teams. The university teams participating in SensUs 2020 are:

	Germany RWTH Aachen		Portugal University of Lisbon
	Scotland University of Glasgow		The Netherlands University of Twente
	United States NC State University		The Netherlands Eindhoven University of Technology
	Egypt The American University in Cairo		Denmark Technical University of Denmark
	England Imperial College London		Canada Université de Montréal
	China Zhejiang University		Sweden Uppsala University
	Switzerland École polytechnique fédérale de Lausanne		Spain BarcelonaTech, University of Vic and University of Barcelona
	Belgium KU Leuven		



SensUs

made possibly by



The international competition on biosensors for health
www.sensus.org